Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology ...

Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities ...

In this article, we are going to take a look at where Arbutus Biopharma Corporation (NASDAQ:ABUS) stands against the other stocks featured in Jim Cramer's Lightning Round. Jim Cramer, the host of ...

Barclays PLC lifted its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 466.3% in the 3rd quarter, according to its most recent 13F filing with the SEC.The firm owned 272,029 ...

It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. Kraft Heinz: "That's the worst ...

WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to ...

The affordable artists’ community in New York has been deteriorating. The $84 million renovation means that 32 out-of-use units will become available. By Anna Kodé The university spent $7 ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to ...

Q3FY25 revenue from operations rose 19.4% to Rs 33,074 crore. The company also saw a 12% YoY increase in average revenue per user (ARPU), reaching Rs 203.3, reflecting strong growth across its key ...